Evidence map›Paper›PMID 33407794›Full record

ArticleJournal of ovarian research2021

Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic premature ovarian failure patients: non-randomized clinical trial, phase I, first in human.

M Mashayekhi, E Mirzadeh, Z Chekini, F Ahmadi, P Eftekhari-Yazdi, S Vesali, T Madani, N Aghdami

2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 49 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 7 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02603744 phase1 / phase2unknown statusnot on this map

Evaluate the Safety and Feasibility of Intra-ovarian Injection of Autologous Adipose Derived Mesenchymal Stromal Cells (ADMSC) in Women With Premature Ovarian Failure(POF)

TypeinterventionalSponsorRoyan InstituteRan2015 to 2018Enrolled9ConditionsPremature Ovarian FailureArmsIntraovarian injection of Adipose derived Stromal cells (ADSCs)
NCT06132542 phase1unknown statusnot on this mapstarted 2024, after this paper: background citation

Autologous Adipose Derived Mesenchymal Stromal Cell Transplantation in Patients With Idiopathic or Drug Induced Premature Ovarian Failure

TypeinterventionalSponsorMongolian National University of Medical SciencesRan2024 to 2024Enrolled10ConditionsPremature Ovarian FailureArmsstem cell therapy
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 7 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. [Stem cell therapy for premature ovarian insufficiency: a review of clinical evidence and therapeutic strategies].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M MashayekhiDepartment of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, P. O Box: 16635-148, Royan Allay, Eastern Hafez St, Banihashem Sq., Resalat Highway, Tehran, Iran.
E MirzadehDepartment of Regenerative Medicine, Cell Sciences Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, P. O Box: 16635-148, Shaghayegh Alley, Banihashem Sq., Resalat Highway, Tehran, Iran.
Z ChekiniDepartment of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, P. O Box: 16635-148, Royan Allay, Eastern Hafez St, Banihashem Sq., Resalat Highway, Tehran, Iran.
F AhmadiDepartment of Reproductive Imaging, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
P Eftekhari-YazdiDepartment of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
S VesaliDepartment of Diabetes, Obesity and Metabolism, Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
T MadaniDepartment of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, P. O Box: 16635-148, Royan Allay, Eastern Hafez St, Banihashem Sq., Resalat Highway, Tehran, Iran. tmadani@royaninstitute.org.
N AghdamiDepartment of Regenerative Medicine, Cell Sciences Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, P. O Box: 16635-148, Shaghayegh Alley, Banihashem Sq., Resalat Highway, Tehran, Iran. nasser.aghdami@royaninstitute.org.
Academic Center for Education, Culture and Research · IRRoyan Institute · IR

Funding

Royan Institute 94000092
6 · The paper itself

Abstract

backgroundPremature ovarian failure (POF) is characterized by the loss of ovarian activity before the age of 40 years. Stem cell therapy has the capability to create a regenerative microenvironment and is a proposed treatment for POF-related infertility due to the presence of renewal folliculogenesis and germ cells in the adult ovaries. In this study, we assessed the safety, feasibility, efficacy and dose adjustment of autologous adipose-derived stromal cells (ADSCs) and their ability to improve ovarian function in POF patients.

methodsThis study was a non-randomized clinical trial, phase I. Nine women with a definitive diagnosis of POF were divided into three groups (n = 3 per group) that received either 5 × 10

resultsParticipants had not shown any early-onset possible side effects and secondary complications during follow-up. The menstruation resumption was observed in four patients which established for several months. In the 15 × 10

conclusionsWe showed the intra-ovarian embedding of ADSCs is safe and feasible and is associated with an inconsistent decline in serum FSH. This should be further investigated with a large RCT.

trial registrationNCT02603744 , Registered 13 November 2015 - Retrospectively registered, http://www.Clinicaltrials.gov.

Indexed as

AdultFeasibility StudiesFemaleHumansMesenchymal Stem CellsOvarian ReservePrimary Ovarian InsufficiencyStem Cell TransplantationYoung AdultAdipose derived mesenchymal stromal cellFSHOvarian volumePremature ovarian failureReturn menstruation

Identifiers

PMID33407794
PMCPMC7786909
OpenAlexW3118757925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.